GLP1 dosing shifts reshape obesity care long term

New evidence suggests some patients may maintain weight loss with less frequent dosing under supervision

Emerging real-world and modeling data suggest that some individuals with obesity may maintain weight loss on GLP-1 therapies even when dosing frequency is reduced, though this approach requires careful patient selection and clinical oversight.

Study Details

GLP-1 receptor agonists such as semaglutide and tirzepatide have become central to obesity treatmen…